Key Takeaways
- Morgan Stanley’s Erin Wright maintains Buy rating on UNH with $375 price objective
- UnitedHealth designated as Wright’s premier selection amid strengthening managed care sentiment
- Updated Medicare Advantage rate disclosure provides enhanced clarity for 2026 payment structure
- First-quarter results scheduled for April 21; analyst consensus projects $6.60 EPS versus $7.20 year-over-year
- Bernstein SocGen maintains Outperform stance with $411 valuation target
Morgan Stanley is entering UnitedHealth’s quarterly report with renewed optimism. Erin Wright, the firm’s analyst covering the sector, reaffirmed her Buy recommendation and maintained a $375 price objective while elevating UnitedHealth to her highest-conviction position within managed care.
UnitedHealth Group Incorporated, UNH
This endorsement arrives following a challenging period for the healthcare giant’s shares. Concerns surrounding Medicare Advantage profitability and elevated medical expense trends have pressured UNH. Wright now contends these obstacles are beginning to dissipate.
Central to her strengthened outlook is the recently released final Medicare Advantage payment schedule. This regulatory update delivered improved transparency regarding 2026 compensation structures and bolstered projections that UNH will continue enhancing MA profitability metrics.
Wright is simultaneously monitoring progress within Optum Health’s restructuring efforts. Following operational challenges in that division, she observes increasing confidence that performance is stabilizing and moving toward recovery.
She additionally highlighted artificial intelligence initiatives as a developing positive catalyst. While still in preliminary phases, Wright believes UnitedHealth’s technology platform investments could deliver substantial operational improvements as they mature.
Q1 Earnings on April 21
UNH releases first-quarter financial results this Tuesday, April 21. Wright anticipates performance largely aligned with expectations, without significant deviations in either direction.
Analyst consensus projects Q1 revenue at $109.52 billion, representing a marginal decline from $109.58 billion during the comparable prior-year period. Earnings per share are forecast at $6.60, down from $7.20 twelve months earlier.
Market participants will scrutinize Medicare Advantage profitability trajectories, medical cost ratio developments, and management commentary regarding Optum Health’s turnaround progress. Artificial intelligence efficiency gains and full-year guidance will command additional attention.
UNH presently trades at $316.40. Against this level, Morgan Stanley’s $375 valuation implies approximately 18.5% potential appreciation.
Bernstein Adds Its Voice
Bernstein SocGen holds an even more constructive view. Analyst Lance Wilkes reaffirmed an Outperform recommendation alongside a $411 price target, characterizing UNH’s current valuation as compelling.
The research firm anticipates broader industry improvement as Medicare Advantage margins rebound from depressed levels following regulatory rate adjustments and competitive capacity reductions.
Bernstein also identifies company-specific margin expansion opportunities as UNH discontinues unprofitable Medicare Advantage and Optum Health offerings. The firm forecasts robust earnings growth through the next four-year horizon.
The equity currently trades at a price-to-earnings multiple of 24. For perspective, the consensus Wall Street price target across 18 Buy ratings and 5 Hold ratings stands at $366.24—suggesting approximately 15.75% upside from present levels.
One noteworthy risk factor: Leerink highlighted that UNH maintains significant exposure to expanded RADV compliance reviews conducted by CMS. Sixty contracts representing 92% of its Medicare Advantage enrollment are currently under examination—a dramatic increase from zero contracts in 2018. These audit processes commenced in April 2025.
UBS also recently incorporated UNH onto its Global High-Quality Dividend Stock List, recognizing it as a dependable dividend-paying investment.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
